• bitcoinBitcoin(BTC)$86,350.000.78%
  • ethereumEthereum(ETH)$2,755.750.27%
  • tetherTether(USDT)$1.000.02%
  • binancecoinBNB(BNB)$789.53-0.48%
  • rippleXRP(XRP)$1.584.52%
  • usd-coinUSDC(USDC)$1.000.01%
  • solanaSolana(SOL)$118.330.66%
  • tronTRON(TRX)$0.343422-1.17%
  • zcashZcash(ZEC)$1,593.438.23%
  • Figure HelocFigure Heloc(FIGR_HELOC)$1.031.79%
  • HyperliquidHyperliquid(HYPE)$96.923.40%
  • dogecoinDogecoin(DOGE)$0.1014432.05%
  • moneroMonero(XMR)$566.84-3.63%
  • whitebitWhiteBIT Coin(WBT)$86.800.64%
  • chainlinkChainlink(LINK)$12.98-0.12%
  • USDSUSDS(USDS)$1.00-0.01%
  • cardanoCardano(ADA)$0.2530503.24%
  • RainRain(RAIN)$0.013083-5.76%
  • leo-tokenLEO Token(LEO)$8.980.18%
  • stellarStellar(XLM)$0.2163371.93%
  • bitcoin-cashBitcoin Cash(BCH)$342.0829.04%
  • uniswapUniswap(UNI)$10.4414.47%
  • nearNEAR Protocol(NEAR)$4.35-0.72%
  • avalanche-2Avalanche(AVAX)$11.07-0.38%
  • Ethena USDeEthena USDe(USDE)$1.000.00%
  • litecoinLitecoin(LTC)$62.712.23%
  • daiDai(DAI)$1.00-0.01%
  • CantonCanton(CC)$0.113863-3.96%
  • USD1USD1(USD1)$1.00-0.01%
  • hedera-hashgraphHedera(HBAR)$0.0995877.91%
  • suiSui(SUI)$1.02-1.49%
  • the-open-networkGram (prev. Toncoin)(GRAM)$1.460.52%
  • shiba-inuShiba Inu(SHIB)$0.0000062.38%
  • BittensorBittensor(TAO)$312.02-1.07%
  • crypto-com-chainCronos(CRO)$0.0671801.55%
  • Global DollarGlobal Dollar(USDG)$1.000.00%
  • MemeCoreMemeCore(M)$1.30-8.78%
  • paypal-usdPayPal USD(PYUSD)$1.00-0.01%
  • tether-goldTether Gold(XAUT)$4,344.57-0.22%
  • okbOKB(OKB)$123.790.28%
  • Circle USYCCircle USYC(USYC)$1.140.01%
  • Ripple USDRipple USD(RLUSD)$1.000.00%
  • BitwayBitway(BTW)$0.9016.84%
  • aaveAave(AAVE)$147.802.47%
  • BlackRock USD Institutional Digital Liquidity FundBlackRock USD Institutional Digital Liquidity Fund(BUIDL)$1.000.00%
  • Ondo US Dollar YieldOndo US Dollar Yield(USDY)$1.140.13%
  • mantleMantle(MNT)$0.685.41%
  • EthenaEthena(ENA)$0.2158901.47%
  • OndoOndo(ONDO)$0.436898-0.69%
  • Pump.funPump.fun(PUMP)$0.004415-1.86%
TradePoint.io
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop
No Result
View All Result
TradePoint.io
No Result
View All Result

Google AI Releases C2S-Scale 27B Model that Translate Complex Single-Cell Gene Expression Data into ‘cell sentences’ that LLMs can Understand

October 17, 2025
in AI & Technology
Reading Time: 4 mins read
A A
Google AI Releases C2S-Scale 27B Model that Translate Complex Single-Cell Gene Expression Data into ‘cell sentences’ that LLMs can Understand
ShareShareShareShareShare

A team of researchers from Google Research, Google DeepMind, and Yale released C2S-Scale 27B, a 27-billion-parameter foundation model for single-cell analysis built on Gemma-2. The model formalizes single-cell RNA-seq (scRNA-seq) profiles as “cell sentences”—ordered lists of gene symbols—so that a language model can natively parse and reason over cellular states. Beyond benchmarking gains, the research team reports an experimentally validated, context-dependent pathway: CK2 inhibition (silmitasertib/CX-4945) combined with low-dose interferon amplifies antigen presentation, a mechanism that could make “cold” tumors more responsive to immunotherapy. The result is ~50% increase in antigen presentation in vitro under the combined condition.

Understanding the model

C2S-Scale converts a high-dimensional expression vector into text by rank-ordering genes and emitting the top-K symbols as a gene-name sequence. This representation aligns single-cell data with standard LLM toolchains and allows tasks such as cell-type prediction, tissue classification, cluster captioning, perturbation prediction, and biological QA to be phrased as text prompts and completions.

YOU MAY ALSO LIKE

The Pros And Cons Of Using A Password Manager Over An Authenticator App

Why Are Some Songs Grayed Out On Apple Music (And How To Fix It)

https://github.com/vandijklab/cell2sentence

Training data, stack, and release

C2S-Scale-Gemma-2-27B is built on Gemma-2 27B (decoder-only Transformer), trained on Google TPU v5, and released under CC-BY-4.0. The training corpus aggregates >800 public scRNA-seq datasets spanning >57M cells (human and mouse) with associated metadata and textual context; pretraining unifies transcriptomic tokens and biological text into a single multimodal corpus.

The key result: an interferon-conditional amplifier

The research team constructed a dual-context virtual screen over >4,000 drugs to find compounds that boost antigen presentation (MHC-I program) only in immune-context-positive settings—i.e., primary patient samples with low interferon tone—while having negligible effect in immune-context-neutral cell-line data. The model predicted a striking context split for silmitasertib (CK2 inhibitor): strong MHC-I upregulation with low-dose interferon, little to none without interferon. The research team reports in-lab validation in human neuroendocrine models unseen in training, with the combination (silmitasertib + low-dose interferon) producing a marked, synergistic increase in antigen presentation (≈50% in their assays).

The amplifier lowers the response threshold to interferon rather than initiating antigen presentation de novo; flow-cytometry readouts show HLA-A,B,C upregulation only under combined treatment (including IFN-β and IFN-γ), across two neuroendocrine models, with representative MFI gains (e.g., 13.6% @10 nM and 34.9% @1000 nM silmitasertib in one model).

Key Takeaways

  • C2S-Scale 27B (Gemma-2) encodes scRNA-seq profiles as textual “cell sentences,” enabling LLM-native single-cell analysis workflows.
  • In a two-context virtual screen (>4,000 compounds), the model predicted an interferon-conditional amplifier: CK2 inhibition (silmitasertib) boosts MHC-I antigen-presentation only with low-dose IFN.
  • Wet-lab tests in human neuroendocrine cell models confirmed the prediction, with ~50% antigen-presentation increase for silmitasertib+IFN versus either alone; this remains preclinical/in vitro.
  • Open weights and usage docs are live on Hugging Face (vandijklab) with both 27B and 2B Gemma variants for research use.

Editorial Comments

C2S-Scale 27B is a technically credible step for LLMs in biology: translating scRNA-seq into “cell sentences” lets a Gemma-2 model run programmatic queries over cell states and perturbations, and in practice it surfaced an interferon-conditional amplifier—silmitasertib (CK2 inhibition)—that increases MHC-I antigen presentation only with low-dose IFN, a mechanism the team then validated in vitro. The value here isn’t headline rhetoric but the workflow: text-native screening across >4k compounds under dual immune contexts to propose a context-dependent pathway that may convert immune-“cold” tumors toward visibility. That said, all evidence is preclinical and bench-scale; the right read is “hypothesis-generating AI” with open weights enabling replication and stress-testing, not a clinical claim.


Check out the Technical Paper, Model on HF, GitHub Page and Technical details . Feel free to check out our GitHub Page for Tutorials, Codes and Notebooks. Also, feel free to follow us on Twitter and don’t forget to join our 100k+ ML SubReddit and Subscribe to our Newsletter. Wait! are you on telegram? now you can join us on telegram as well.

The post Google AI Releases C2S-Scale 27B Model that Translate Complex Single-Cell Gene Expression Data into ‘cell sentences’ that LLMs can Understand appeared first on MarkTechPost.

Credit: Source link

ShareTweetSendSharePin

Related Posts

The Pros And Cons Of Using A Password Manager Over An Authenticator App
AI & Technology

The Pros And Cons Of Using A Password Manager Over An Authenticator App

September 23, 2026
Why Are Some Songs Grayed Out On Apple Music (And How To Fix It)
AI & Technology

Why Are Some Songs Grayed Out On Apple Music (And How To Fix It)

September 22, 2026
Motorola’s New Signature 27 Is Among The First Smartphone To Use The Snapdragon 8 Elite Extreme Gen 6 Processor
AI & Technology

Motorola’s New Signature 27 Is Among The First Smartphone To Use The Snapdragon 8 Elite Extreme Gen 6 Processor

September 22, 2026
Anthropic Releases Claude Opus 5.5: Fable 5.1-Level Performance at 40% Lower Running Cost Than Opus 5
AI & Technology

Anthropic Releases Claude Opus 5.5: Fable 5.1-Level Performance at 40% Lower Running Cost Than Opus 5

September 22, 2026
Next Post
Baidu’s PaddlePaddle Team Releases PaddleOCR-VL (0.9B): a NaViT-style + ERNIE-4.5-0.3B VLM Targeting End-to-End Multilingual Document Parsing

Baidu’s PaddlePaddle Team Releases PaddleOCR-VL (0.9B): a NaViT-style + ERNIE-4.5-0.3B VLM Targeting End-to-End Multilingual Document Parsing

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

No Result
View All Result
Current with Christine Romans – Aug. 31 | NBC News NOW

Current with Christine Romans – Aug. 31 | NBC News NOW

September 20, 2026
Ted Cruz says Ken Paxton can ‘absolutely win’ Texas Senate race: Full interview

Ted Cruz says Ken Paxton can ‘absolutely win’ Texas Senate race: Full interview

September 21, 2026
Michael Minogue wins Massachusetts Republican governor primary, NBC News projects

Michael Minogue wins Massachusetts Republican governor primary, NBC News projects

September 19, 2026

About

Learn more

Our Services

Legal

Privacy Policy

Terms of Use

Bloggers

Learn more

Article Links

Contact

Advertise

Ask us anything

©2020- TradePoint.io - All rights reserved!

Tradepoint.io, being just a publishing and technology platform, is not a registered broker-dealer or investment adviser. So we do not provide investment advice. Rather, brokerage services are provided to clients of Tradepoint.io by independent SEC-registered broker-dealers and members of FINRA/SIPC. Every form of investing carries some risk and past performance is not a guarantee of future results. “Tradepoint.io“, “Instant Investing” and “My Trading Tools” are registered trademarks of Apperbuild, LLC.

This website is operated by Apperbuild, LLC. We have no link to any brokerage firm and we do not provide investment advice. Every information and resource we provide is solely for the education of our readers. © 2020 Apperbuild, LLC. All rights reserved.

No Result
View All Result
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop

© 2023 - TradePoint.io - All Rights Reserved!